Genetic Modifier LTBP4 Stratification of Proteomics Points to Interacting IL-23/IL-6/IL-17D Pathways in Severity of DMD (ICNMD 2026) - Jul 6, 2026 - Abstract #OS01.02; Pres time: Jul 8, 2026; 05:00 PM - 05:15 PM; Location: Spadolini Attic - Hall 3; "For validated modifiers, we stratified serum profiles at baseline by genotype to identify candidate cellular responses associated with clinical severity. Participants in clinical trials (VBP15-002/003 n=48; VBP15-004 n=131) were genotyped for genetic modifier loci (n=110 genotyped)... Significant associations with improved baseline motor outcomes in young steroid naïve DMD children were found for LTBP4 and DYNLT5 loci IL-23, IL-6 and IL-17D interacting pathways may participate in disease progression."
IO biomarker • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy • ADRB2 • CD40 • IL23A • IL6 • SPP1 • TNFRSF10A
|
|
Prof. Eric Hoffman; Assoc. Prof. Utkarsh Dang; Asst. Prof. Yuan Fang; Dr. Daniele Sabbatini; Prof. Elena Pegoraro; Assoc. Prof. Luca Bello; Prof. Paula Clemens; Prof. Michela Guglieri; Prof. Johannes van den Anker; Dr. Jesse Damsker; Dr. Laura Hagerty; Prof. Yetrib Hathout; Miss Lauren Morgenroth; Prof. Kanneboyina Nagaraju; Prof. Jyoti Jaiswal
|